Quantcast
Last updated on April 20, 2014 at 17:20 EDT

Latest Alemtuzumab Stories

2009-01-20 07:00:00

An Agent Showing Improvement in Overall Response Rate Would Earn Higher Patient Share in U.S. Than Europe, According to a New Report from Decision Resources WALTHAM, Mass., Jan. 20 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that GlaxoSmithKline's ofatumumab will become Decision Resources' proprietary clinical gold-standard treatment for relapsed/refractory chronic lymphocytic leukemia...

2008-12-09 07:00:00

Data Showed Campath May Lead to Overall Survival in Patients with Poor Prognostic Factors SAN FRANCISCO, Dec. 9 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc. today announced results from three studies showing that treatment with Campath(R) (alemtuzumab) showed activity in high-risk chronic lymphocytic leukemia (CLL) patients who have poor prognostic indicators. These findings were presented at the 50th Annual Meeting of the American Society of Hematology in San Francisco,...

2008-12-08 12:59:00

Data from a pivotal trial suggests that ofatumumab has activity in heavily pre-treated patients who have failed standard treatments PHILADELPHIA, Dec. 8 /PRNewswire-USNewswire/ -- GlaxoSmithKline (GSK) and Genmab A/S (OMX: GEN) announced today positive results from a pivotal trial pre-planned interim analysis of Arzerra(TM) (ofatumumab) in the treatment of refractory chronic lymphocytic leukemia (CLL). The results demonstrate the potential of ofatumumab for heavily pre-treated patients with...

2008-12-05 14:45:00

WAYNE, N.J., Dec. 5 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc. announced today that data on Campath(R) (alemtuzumab) and Leukine(R) (sargramostim) will be presented at the 50th Annual Meeting of the American Society of Hematology (ASH) from December 6-9, 2008 in San Francisco, California. Clinical investigators from leading oncology and hematology research centers will present data through several oral and poster presentations reporting important findings in leukemia-related...

69f96049fb2993a4f81399f887bdfe8d1
2008-10-23 15:56:08

A drug developed for patients with leukemia also appears to regenerate brain cells and reverse the effects of relapsing-remitting multiple sclerosis, British researchers said on Wednesday. Bayer AG and Genzyme Corp's alemtuzumab, marketed under the brand name Campath, showed long-term improvement in disability in a three-year study, said Alasdair Cole, a neurologist at the University of Cambridge. Multiple sclerosis is an autoimmune condition in which the immune system damages the central...

2008-10-23 12:00:00

Genzyme and Bayer have reported Phase II study results demonstrating the potential of alemtuzumab in treatment-naive MS patients. Although the product's efficacy is now established, two recently initiated Phase III trials will reveal whether alemtuzumab should be used as an early treatment or if safety issues will restrict it to patients who continue to relapse on currently approved MS therapies. Results from the final three-year analysis of the 334-patient CAMMS223 study showed that...

2008-10-23 06:00:27

By Rita Rubin A leukemia drug was about 70% more effective than a standard therapy in treating early multiple sclerosis, according to clinical trial results in today's New England Journal of Medicine. In multiple sclerosis, or MS, the immune system attacks myelin, the sheath that enables nerve cells to conduct impulses between the brain and other parts of the body. The drug, alemtuzumab, depletes the body of the white blood cells that attack myelin, which are eventually replaced by...

2008-10-22 18:00:09

Genzyme Corporation (Nasdaq: GENZ) and Bayer HealthCare Pharmaceuticals Inc. today announced study results showing that patients with early relapsing-remitting multiple sclerosis (RRMS) taking once-yearly cycles of alemtuzumab reduced their risk of relapse by 74 percent and the risk of sustained accumulation of disability by 71 percent compared to patients treated with the active comparator Rebif(R) (high-dose interferon beta-1a). Importantly, the mean disability of patients on alemtuzumab...

2008-08-12 03:00:18

By Anonymous United Kingdom - Bayer Schering Pharma AG and Genzyme Europe BV have informed physicians of six infectionrelated deaths, reported from a trial (CALGB10101) in which previously untreated, symptomatic B-cell chronic lymphocytic leukemia (CLL) patients were treated with fludarabine and rituximab followed by alemtuzumab for remission consolidation. Alemtuzumab (MabCampath(R)) is approved for the treatment of patients with B-cell chronic lymphocytic leukaemia (BCLL) for whom...

2008-07-31 12:01:05

COPENHAGEN, July 31 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) and GlaxoSmithKline (LSE and NYSE: GSK) announced today positive top-line results from an interim analysis of the Phase III pivotal study evaluating ofatumumab (HuMax-CD20(R)) to treat two groups of chronic lymphocytic leukemia (CLL) patients with high unmet medical need. At the interim analysis, the study met the primary endpoint in both populations and the results from the secondary endpoints also support the primary...